Form 4: Spyre Therapeutics: Insider Conversion of Preferred Stock

Fairmount Funds Management LLC and its affiliates reported the conversion of Series B Preferred Stock into common stock, alongside a sale of common stock.

Summary

• Fairmount Funds Management LLC, acting as investment manager for Fairmount Healthcare Fund II L.P., along with individuals Tomas Kiselak and Peter Harwin, reported transactions related to Spyre Therapeutics, Inc. (SYRE).
• On June 23, 2026, 16,667 shares of Series B Preferred Stock were converted into 666,680 shares of Common Stock for no cash consideration.
• This conversion was subject to beneficial ownership limitations, preventing any holder from exceeding 9.99% of the outstanding common stock post-conversion.
• Concurrently, on the same date, 4,684,781 shares of Common Stock were disposed of at a price of $85.31 per share.
• Following these transactions, Fairmount Healthcare Fund II L.P. beneficially owns 4,684,781 shares of common stock indirectly.
• Tomas Kiselak and Peter Harwin also hold common stock indirectly, with 406,038 shares each.
• The filing also notes the existence of Series A Preferred Stock, convertible into common stock under similar limitations.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of common stock by a major holder, despite the conversion of preferred stock.

Positives

• Conversion of preferred stock into common stock can indicate confidence in the company's future prospects.
• The conversion was executed without cash consideration, suggesting a strategic internal restructuring rather than a cash-intensive event.

Negatives

• A significant disposition of 4,684,781 shares of common stock at $85.31 per share indicates a substantial sell-off by a major holder.
• The beneficial ownership limitations (9.99%) suggest potential concerns about maintaining control or avoiding regulatory scrutiny with large holdings.

Risks

• The large sale of common stock could put downward pressure on the stock price.
• The beneficial ownership limitations may restrict future conversion or holding strategies for preferred stockholders.
• Potential for further sales by related entities if they also hold significant positions.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance. However, the conversion of preferred stock and subsequent sale of common stock by a major holder could signal a shift in their investment strategy or a realization of gains.

Management Comments

• Fairmount Funds Management LLC is the investment manager for Fairmount Healthcare Fund II L.P.
• The managers of Fairmount are Peter Harwin and Tomas Kiselak.
• Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
• Tomas Kiselak serves on the board of directors of Issuer and is also a Managing Member of Fairmount Funds Management LLC, leading to potential deputization as a director.

Industry Context

StockSavvy.ai notes that Form 4 filings are crucial for understanding insider activity. The conversion of preferred stock to common stock is a common event, but the simultaneous large sale by a significant holder like Fairmount Funds Management warrants close attention from investors regarding potential shifts in institutional sentiment or strategic portfolio adjustments within the biotechnology or pharmaceutical sector.

Related Party Transactions

• Fairmount Funds Management LLC acts as the investment manager for Fairmount Healthcare Fund II L.P.
• Peter Harwin and Tomas Kiselak are managers of Fairmount Funds Management LLC and may be deemed to have beneficial ownership through their roles, though they disclaim it except for pecuniary interest.

Stakeholder Impact

• Shareholders: The sale of a large block of shares by a significant holder could impact share price and liquidity.
• Management/Board: The conversion and sale might reflect strategic decisions by the investment fund that manages significant stakes, potentially influencing board dynamics if the fund's representation changes.

Next Steps

• Monitor future filings from Fairmount Funds Management LLC and related entities for any further transactions.
• Observe the market reaction to the reported sale of common stock.

Key Dates

Recommendation

The filing reports a significant sale of common stock by a major holder, which could be a negative signal. However, the conversion of preferred stock is a neutral event. Without more context on the company's performance or the reason for the sale, a 'hold' recommendation is prudent, suggesting investors wait for further clarity before making significant decisions.

Keywords

Spyre Therapeutics, SYRE, Form 4, Insider Trading, Preferred Stock Conversion, Common Stock Sale, Fairmount Funds Management, Beneficial Ownership, SEC Filing